Amryt Pharma PLC's (NASDAQ:AMYT) (LON:AMYT) Joe Wiley talks to Proactive London's Katie Pilbeam after revealing 'positive results' from the phase III success of FILSUVEZ, a gel for a rare and extremely painful skin condition called epidermolysis bullosa (EB).
The results showed which products increased the speed of wound healing in the disease and if approved, this would be the first available treatment for EB.
Wiley explains the challenges of such a trial which involved 223 people, 156 of which were children to research a disease that impacts over 500,000 people worldwide.
